ProCE Banner Activity


New Perspectives on the Treatment of Multiple Myeloma in the Relapse Setting: Case Discussion and Common Clinical Scenarios

In this on-demand webcast on treating relapsed multiple myeloma, experts describe considerations and therapeutic strategies in the early relapse setting and heavily pretreated disease and discuss emerging novel therapies.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 15, 2022

Expiration: November 14, 2023



Sagar Lonial

Sagar Lonial, MD, FACP

Professor and Chair
Department of Hematology and Medical Oncology
Emory University
Atlanta, Georgia

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Bristol Myers Squibb

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan therapeutic strategies for patients with MM in the relapse setting based on current available data, individual patient and disease characteristics, and response to and tolerance of prior therapy
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Address challenges of access to CAR T-cell therapy and use of bridging strategies in patients with MM in the relapse setting
  • Mitigate treatment-related adverse events associated with new or novel MM treatments in the relapse setting
  • Identify patients with MM in the relapse setting who would be eligible for enrollment in clinical trials


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Professor and Chair
Department of Hematology and Medical Oncology
Emory University
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Takeda; researcher: Bristol-Myers Squibb, Janssen, Novartis, Takeda; board member with stock: TG Therapeutics.

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD: consultant: GlaxoSmithKline; researcher: Amgen, Janssen, Sanofi, Seattle Genetics.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 15, 2022, through November 14, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma in the relapse setting.